The following AKT2 reagents supplied by CUSABIO are manufactured under a strict quality control system. Multiple applications have been validated and solid technical support is offered.

AKT2 Antibodies

AKT2 Antibodies for Homo sapiens (Human)

AKT2 Antibodies for Arabidopsis thaliana (Mouse-ear cress)

AKT2 Proteins

AKT2 Proteins for Homo sapiens (Human)

AKT2 Proteins for Rattus norvegicus (Rat)

AKT2 Proteins for Mus musculus (Mouse)

AKT2 Proteins for Arabidopsis thaliana (Mouse-ear cress)

AKT2 Background

RAC-beta serine/threonine-protein kinase (AKT2) is an enzyme that in humans is encoded by the AKT2 gene [1], which is a putative oncogene. AKT2 regulates many processes, including metabolism, proliferation, cell survival, growth, and angiogenesis. All these processes are mediated through serine and/or threonine phosphorylation of a range of downstream substrates. AKT2 might serve as a more direct and specific kinase mediating Glucocorticoid resistance through FoxO3a/Bim signaling pathway. And AKT2 inhibition may be explored as a promising target for treating Glucocorticoids-resistant hematopoietic malignancies [2]. CDK9 acts as a proto-oncogene in cervical cancer and modulates cell proliferation and apoptosis through the AKT2/p53 pathway [3]. AKT2 increases the migration and invasion of ovarian cancer cells in vitro and promotes lung metastasis in nude mice in vivo through PKM2-mediated elevation of STAT3 expression and NF-kappaB activation [4]. Tang Y et al. provided evidence suggesting that AKT2 drives de novo lipogenesis in adipocytes by stimulating ChREBP beta transcriptional activity. The AKT2-ChREBP pathway in brown adipose tissue could optimize fuel storage and thermogenesis [5]. MiR-92a could inhibit the proliferation and migration of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLSs) by regulating AKT2 expression [6].

[1] Cheng JQ, Godwin AK, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas [J]. Proc Natl Acad Sci U S A. November 1992, 89 (19): 9267-71.
[2] Xie M, Yang A, et al. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal [J]. Cell Death Dis. 2019 Jan 1;9(10):1013. doi: 10.1038/s41419-018-1043-6.
[3] Xu J, Xu S,et al. Cyclin-dependent kinase 9 promotes cervical cancer development via AKT2/p53 pathway [J]. IUBMB Life. 2019 Mar;71(3):347-356.
[4] Zheng B, Geng L, et al. AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-kappaB axis [J]. Cell Signal. 2018 May;45:122-131.
[5] Sanchez-Gurmaches J, Tang Y, et al. Brown Fat AKT2 Is a Cold-Induced Kinase that Stimulates ChREBP-Mediated De Novo Lipogenesis to Optimize Fuel Storage and Thermogenesis [J]. Cell Metab. 2018 Jan 9;27(1):195-209.e6.
[6] Yu FY, Xie CQ, et al. MiR-92a inhibits fibroblast-like synoviocyte proliferation and migration in rheumatoid arthritis by targeting AKT2 [J]. J Biosci. 2018 Dec;43(5):911-919.

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1